Resource type
All
Topics

Whitepaper

90% of GLP-1 demand never becomes therapy

Demand for glucagon-like peptide-1 therapies has never been clearer. Yet for obesity-indicated GLP-1s, 90 percent of that demand never becomes treatment. Payer rejections, cost concerns and early drop-off…

Advertisement